AstraZeneca
AZ-Targacept depression candidate moves into phase IIb
February 9, 2011Research and Development AZ, AstraZeneca, TC-5214, Targacept, depression, major depressive disorder
AstraZeneca and Targacept have begun a phase IIb trial of TC-5214 as a ‘switch’ monotherapy for patients with depression. The …
AZ and Pfizer support personalised medicine database
February 8, 2011Research and Development AZ, AstraZeneca, Cancer Research UK, Iressa, Pfizer, crizotinib, gefitinib, personalised medicine
AstraZeneca and Pfizer have teamed up with leading charity Cancer Research UK to help develop its stratified medicines programme. Stratified …
Late-stage blow to AstraZeneca’s prostate cancer drug
February 7, 2011Research and Development AstraZeneca, Cancer, prostate cancer, zibotentan
A late-stage trial of AstraZeneca’s oral prostate cancer drug zibotentan has been halted after it failed to meet its primary …
AstraZeneca revenues reach standstill
January 31, 2011Sales and Marketing AstraZeneca, Full year 2010, patent expiry, results
AstraZeneca’s revenues came to a virtual standstill in 2010, with strong growth outside the US being offset by generic competition …
AstraZeneca takes $445m hit to halt motavizumab
December 22, 2010Research and Development AZ, AstraZeneca, MedImmune, motavizumab, respiratory, respiratory syncytial virus
AstraZeneca has withdrawn a US licence application for its biologic respiratory treatment motavizumab in a move that will cost the …
AstraZeneca appoints Esra Erkal Paler head of global media relations
December 22, 2010Medical Communications AstraZeneca, Esra Erkal Paler, appointment, medical communications
AstraZeneca has appointed Esra Erkal Paler to head up its worldwide media relations activities. She will lead the company’s London-based …
FDA delays approval of AstraZeneca’s Brilinta
December 20, 2010Research and Development, Sales and Marketing AZ, AstraZeneca, Brilinta, Brilique, acute coronary syndrome
US regulators have delayed approving AstraZeneca’s antiplatelet tablet Brilinta (ticagrelor) because their want more information about a crucial clinical trial. …
China to ‘overtake US in innovation by 2020’
December 13, 2010Research and Development, Sales and Marketing AstraZeneca, China, India, innovation
China will replace the US as the number one ‘powerhouse of innovation’ within the next ten years according to a …
Hormone therapy drugs ‘increase heart disease risk’
December 10, 2010Research and Development AstraZeneca, Hormone therapy, Novartis, Pfizer, aromatase inhibitors, breast cancer, tamoxifen
Three aromatase inhibitors could increase the risk of heart disease in postmenopausal women with breast cancer, according to new data. …
Digital Pharma: AZ launches its first UK iPhone app
December 8, 2010Medical Communications Apple, AstraZeneca, Digital Pharma blog, apps, ipad, iphone
AstraZeneca has launched an iPhone app to provide UK healthcare professionals with information on genetic tests for lung cancer. The …
AZ’s Brilique approved in Europe
December 7, 2010Sales and Marketing AZ, AstraZeneca, Brilique, Plavix, acute coronary syndromes, antiplatelet, atherothrombotic events, ticagrelor
European regulator have approved AstraZeneca’s oral antiplatelet Brilique (ticagrelor tablets). Brilique can now be used for the prevention of atherothrombotic …
EU regulators launch fresh raids on pharma
December 7, 2010Sales and Marketing AstraZeneca, European Commission, Losec, Nexium, Nycomed, Pantazol, Ratiopharm, antitrust investigation, esomeprazole, pantoprazole
Competition regulators from the EU have raided offices of AstraZeneca and Nycomed in connection with alleged attempts to block generic …
AstraZeneca staff strike as pension talks breakdown
November 15, 2010Manufacturing and Production AZ, AstraZeneca, AstraZeneca UK Manufacturing, GMB, Hurdsfield Industrial Estate, pensions, strikes, unions
Workers at an AstraZeneca facility in the UK went back on strike for the eighth time last week after talks …
Patent expiries bite into AstraZeneca revenues
October 29, 2010Sales and Marketing AstraZeneca, Crestor, Q3, Seroquel
Generic competition and a major drop off in pandemic influenza products saw AstraZeneca’s revenue fall for the third quarter. Revenue …
Watson submits Crestor copycat
October 28, 2010Sales and Marketing AstraZeneca, Crestor, Watson, generic, patent
Watson Pharmaceuticals is seeking to launch a generic version of AstraZeneca cholesterol blockbuster Crestor, exploiting weaknesses in its patent. The …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
